News

"Hospira’s acquisition of the Orchid API facility will support supply continuity of key beta-lactam antibiotic products, improve our cost position and pave the way for future API development,"

Anoro is a once-daily combination treatment comprised of two bronchodilators, umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), and vilanterol (VI), a long-acting beta2 agonist (LABA), in a single

Dovobet® Ointment is a topical combination of active vitamin D3 calcipotriol and the corticosteroid betamethasone dipropionate. LEO Pharma K.K. filed an application for approval to the Ministry of

The acquisition includes one product marketed under an Abbreviated New Drug Application (ANDA) – Ursodiol tablet – and one approved ANDA that is not yet marketed – Lamotrigine

Alectinib’s approval was based on data from a Japanese Phase I/II clinical trial (AF-001JP) for people whose tumours were advanced, recurrent or could not be removed completely through

The approval is based on data from the Phase III DECISION (stuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine refractory thyrOid caNcer) trial. In

"We believe these new development initiatives will further increase the value of Celladon’s pipeline and potentially allow us to broaden the clinical utility of MYDICAR for a wide

The marketing authorisation is for a new indication for the use of Arzerra (ofatumumab) in combination with chlorambucil or bendamustine to treat patients with chronic lymphocytic leukaemia (CLL)

The completed acquisition concerns products primarily intended for Asia including Japan, South Korea and Europe excluding some countries. Santen’s payment for the closed transaction totalled about $550m and